Paclitaxel versus sirolimus eluting stents in diabetic patients: Does stent type and/or stent diameter matter?: Long-term clinical outcome of 2,429-patient multicenter registry

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 1, 2013, Pages 80-89

  Tarantini, Giuseppe ^a   Facchin, Michela ^a   Capodanno, Davide ^b   Musumeci, Giuseppe ^c   Saia, Francesco ^d   Menozzi, Alberto ^e   Meliga, Emanuele ^f   Mancone, Massimo ^g   Lettieri, Corrado ^h   Tamburino, Corrado ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

^f MAURIZIANO HOSPITAL   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h CARLO POMA HOSPITAL   (Italy)

Author keywords

coronary artery disease; diabetes; percutaneous coronary intervention; stent

Indexed keywords

PACLITAXEL; RAPAMYCIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; SENSITIVITY ANALYSIS;

AGED; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; PATIENT SAFETY; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; PROSTHESIS FAILURE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871716871     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24445     Document Type: Article

References (25)

1. Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD, Laskey WK, Williams DO, Smith C, Anderson WD, Lee JS, Srinivas V, Kelsey SF, Kip KE,. Impact of drug-eluting stents among insulin-treated diabetic patients: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008; 1: 139-147.
2. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P,. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
3. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP, the REALITY Trial Investigators. Sirolimus- vs. paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA 2006; 295: 895-904.
4. Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B,. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
5. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE,. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005; 112: 2833-2839.
6. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A,; the ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
7. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ,. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008; 52: 727-733.
8. Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffrè G, Prati F, Tamburino C, Ribichini F,. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: A prospective, randomized, multicenter study. Diabetes Care 2008; 31: 15-19.
9. Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lüscher TF, Garachemani A, Hess OM, Wandel S, Meier B, Jüni P, Windecker S,. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007; 50: 1123-1131.
10. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A,. Vessel size and outcome after coronary drug-eluting stent placement results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48: 1304-1309.
11. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, Leibundgut G, Bader F, Kaiser C,; the BASKET Investigators. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: Does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30: 16-24.
12. Austin PC, Grootendorst P, Anderson GM,. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat Med 2007; 26: 734-753.
13. Klein JP, Moeschberger ML,. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer-Verlag; 1997.
14. Chiu M, Ko DT, Austin PC, Cohen EA, Velianou JL, Goeree R, Blackhouse G, Tu JV,. Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients. Circ Cardiovasc Qual Outcomes 2009; 2: 96-107.
15. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PPT, Sianos G, van Domburg RT, Serruys PW,. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28: 26-32.
16. Kim JS, Lee BH, Ko YG, Choi D, Jang Y, Min PK, Yoon YW, Hong BK, Kwon HM, Ahn KS, Lee SH, Yoon JH, Lee BK, Kim BO, Kim BK, Oh SJ, Jeon DW, Yang JY, Cho JR, Jung JH, Ryu SK,; for the KOrean Multicenter Angioplasty TEam (KOMATE) Investigators. Comparison of sirolimus-eluting stent and paclitaxel- eluting stent for long-term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry. Catheter Cardiovasc Interv 2008; 72: 601-607.
17. Wolf WM, Vlachos HA, Marroquin OC, Lee JS, Smith C, Anderson WD, Schindler JT, Holper EM, Abbott JD, Williams DO, Laskey WK, Kip KE, Kelsey SF, Mulukutla SR,. Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus a report from the national heart, lung, and blood institute dynamic registry. Circ Cardiovasc Interv 2010; 3: 42-49.
18. Zhang F, Dong L, Ge J,. Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol 2010; 105: 64-68.
19. Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L,. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: The diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 2009; 103: 345-349.
20. Finn AV, Nakazawa G, Kolodgie FD, Virmani R,. Temporal course of neointimal formation after drug-eluting stent placement: Is our understanding of restenosis changing? JACC Cardiovasc Interv 2009; 2: 300-302.
21. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ,. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. 4-Years clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) Trial. JACC Cardiovasc Interv 2011; 4: 310-316.
22. Onuma Y, Wykrzykowska JJ, Garg S, Vranckx P, Serruys PW,; ARTS I and II Investigators. 5-Years follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease. Insights from ARTS (arterial revascularization therapy study)-II and ARTS-I Trials. JACC Cardiovasc Interv 2011; 4: 317-323.
23. Carter AJ,. TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv 2004; 61: 233-236.
24. Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW,. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: Results from the SPIRIT IV clinical trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system). J Am Coll Cardiol 2010; 56: 2084-2089.
25. Hanna NN, Gaglia MA Jr, Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R,. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 2010; 106: 504-510.